Design: Systematic review and meta-analysis of longitudinal studies
Population: 32 studies of patients with head and neck cancer
Primary outcome: Overall survival by pretreatment quality-of-life domain
Effect: Global QoL HR 1.11 (1.08-1.14); physical functioning HR 1.16 (1.13-1.20) per 10-point worsening

This meta-analysis pooled 32 studies that measured patient-reported quality of life before treatment for head and neck cancer, harmonising estimates to a 10-point worsening.

Worse global quality of life (HR 1.11, 95% CI 1.08-1.14), physical functioning (HR 1.16, 1.13-1.20), role functioning and social functioning were each associated with higher mortality, and these held when studies were removed one at a time. Associations for swallowing and breathlessness were less stable.

This is prognostic, not causal. Poor quality-of-life scores may reflect more advanced disease, frailty or comorbidity.

The practical use is as a cheap, patient-reported marker of who may need more supportive care from the start, not as a treatment target in itself.

Each 10-point worsening in pretreatment physical functioning was linked to about 16% higher mortality.
Global, role and social functioning scores were also consistently prognostic.
Collect a validated quality-of-life questionnaire before treatment begins.
Use low scores to prioritise early supportive-care referral.
Do not treat a low score as a target that will change survival on its own.

Why it matters

A questionnaire most clinics already have adds prognostic information beyond stage.

The statistics, in plain English

A hazard ratio of 1.16 per 10 points means each 10-point drop is linked to about 16% higher risk of death over follow-up. Because these are adjusted observational associations, residual confounding remains possible.